Achmea Investment Management B.V. Has $3.15 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Achmea Investment Management B.V. decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 15.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 42,612 shares of the medical research company’s stock after selling 7,778 shares during the period. Achmea Investment Management B.V.’s holdings in Edwards Lifesciences were worth $3,154,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in Edwards Lifesciences by 86.3% during the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Jennison Associates LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $555,939,000. Assenagon Asset Management S.A. grew its stake in Edwards Lifesciences by 475.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares during the period. Raymond James Financial Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $213,844,000. Finally, Jacobs Levy Equity Management Inc. grew its stake in Edwards Lifesciences by 239.9% in the third quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company’s stock valued at $243,745,000 after acquiring an additional 2,606,950 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Piper Sandler raised their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Truist Financial reissued a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Morgan Stanley raised their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Finally, Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $68.00 to $71.00 and gave the company a “hold” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Trading Up 2.1 %

EW opened at $69.37 on Friday. The business has a 50 day simple moving average of $71.74 and a two-hundred day simple moving average of $70.32. The firm has a market capitalization of $40.78 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This represents a 26.91 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now directly owns 60,372 shares in the company, valued at $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 53,803 shares of company stock worth $3,900,976. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.